Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (21-30 of 244) with videos related to

Pageof 25
Sort By:
Critical Reviews in Oncology/Hematology|May 19, 2022
Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational researchSophia K Khaldoyanidi, Antreas Hindoyan, Anthony Stein, et al.
Leukemia|May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developmentsNaval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
Deutsche Medizinische Wochenschrift (1946)|July 14, 2018
[Challenges in Immuno-Oncology - Possibilities for Optimization]Alexander Shimabukuro-Vornhagen, Marion Subklewe, Michael von Bergwelt-Baildon
Immunotherapy|December 22, 2012
Current strategies in immunotherapy for acute myeloid leukemiaFelix S Lichtenegger, Frauke M Schnorfeil, Wolfgang Hiddemann, et al.
Journal of Hematology & Oncology|October 10, 2015
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabThomas Köhnke, Christina Krupka, Johanna Tischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Immune Biology of Acute Myeloid Leukemia: Implications for ImmunotherapySophia Khaldoyanidi, Dirk Nagorsen, Anthony Stein, et al.
Oncology Research and Treatment|November 19, 2024
Survivorship in Chimeric Antigen Receptor T-Cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse MortalityTobias Tix, Marion Subklewe, Michael von Bergwelt-Baildon, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2021
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigensGerulf Hänel, Caroline Angerer, Katja Petry, et al.
Journal of Hematology & Oncology|July 27, 2017
Recent developments in immunotherapy of acute myeloid leukemiaFelix S Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|January 25, 2026
The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapyKathrin Gabriel, Lucie Heinzerling, Louisa von Baumgarten, et al.
Pageof 25

Showing results (21-30 of 244) with videos related to

Sort By:
Pageof 25
Critical Reviews in Oncology/Hematology|May 19, 2022
Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational researchSophia K Khaldoyanidi, Antreas Hindoyan, Anthony Stein, et al.
Leukemia|May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developmentsNaval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
Deutsche Medizinische Wochenschrift (1946)|July 14, 2018
[Challenges in Immuno-Oncology - Possibilities for Optimization]Alexander Shimabukuro-Vornhagen, Marion Subklewe, Michael von Bergwelt-Baildon
Immunotherapy|December 22, 2012
Current strategies in immunotherapy for acute myeloid leukemiaFelix S Lichtenegger, Frauke M Schnorfeil, Wolfgang Hiddemann, et al.
Journal of Hematology & Oncology|October 10, 2015
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabThomas Köhnke, Christina Krupka, Johanna Tischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Immune Biology of Acute Myeloid Leukemia: Implications for ImmunotherapySophia Khaldoyanidi, Dirk Nagorsen, Anthony Stein, et al.
Oncology Research and Treatment|November 19, 2024
Survivorship in Chimeric Antigen Receptor T-Cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse MortalityTobias Tix, Marion Subklewe, Michael von Bergwelt-Baildon, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2021
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigensGerulf Hänel, Caroline Angerer, Katja Petry, et al.
Journal of Hematology & Oncology|July 27, 2017
Recent developments in immunotherapy of acute myeloid leukemiaFelix S Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|January 25, 2026
The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapyKathrin Gabriel, Lucie Heinzerling, Louisa von Baumgarten, et al.
Pageof 25